Carbohydrate Use During and Following Exercise (CHO-use)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified October 2012 by Maastricht University Medical Center
Sponsor:
Information provided by (Responsible Party):
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT01709617
First received: October 11, 2012
Last updated: October 16, 2012
Last verified: October 2012
  Purpose

Carbohydrates are an integral component of sports nutrition. Providing carbohydrate (CHO) during exercise delays the onset of fatigue and improves exercise performance by maintaining high rates of CHO oxidation. Traditionally, glucose, or glucose polymers have been the preferential CHO source found in sports drinks. However, during the intestinal absorption of large amounts of glucose (>1.2 g/min), sodium-dependent glucose transporters (SGLT1) may become fully saturated, potentially limiting the rate of exogenous CHO oxidation. In an effort to evade this limitation, research has suggested using multiple transportable carbohydrates in the composition of sports drinks. Multiple transportable carbohydrates are combinations of simple sugars that use different intestinal transporters during the absorption process. Ingesting multiple transportable carbohydrates may enhance the capacity for total intestinal CHO absorption, leading to an increase in the rate of exogenous CHO oxidation. Our purpose will be to examine the disaccharide sucrose in it's ability to provide exogenous fuel during and following prolonged exercise.


Condition Intervention
Carbohydrate Oxidation and Glycogen Utilization During and Following Exercise
Dietary Supplement: Carbohydrate ingestion

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Official Title: Sucrose as a Preferred Carbohydrate in Sports Nutrition

Resource links provided by NLM:


Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • Exogenous carbohydrate oxidation rate (Part A) [ Time Frame: 0 min during trials 1-3 ] [ Designated as safety issue: No ]
    Carbohydrate oxidation as measured by breath samples

  • Endogenous carbohydrate oxidation (Part A) [ Time Frame: 0 min during trials 1-3 ] [ Designated as safety issue: No ]
    endogenous carbohydrate oxidation as measured through breath samples during trials 1-3

  • Glycogen utilization (Part B) [ Time Frame: immediately post exercise (~90min), during trials 4-6 ] [ Designated as safety issue: No ]

    Glycogen utilization measured through a muscle biopsy sample at post (~90 min), 3 and 6 h post exercise.

    Part B; trials 4-6.


  • Exogenous carbohydrate oxidation rate (Part A) [ Time Frame: 30 min during trials 1-3 ] [ Designated as safety issue: No ]
    Carbohydrate oxidation as measured by breath samples

  • Exogenous carbohydrate oxidation rate (Part A) [ Time Frame: 60 min during trials 1-3 ] [ Designated as safety issue: No ]
    Carbohydrate oxidation as measured by breath samples

  • Exogenous carbohydrate oxidation rate (Part A) [ Time Frame: 90 min during trials 1-3 ] [ Designated as safety issue: No ]
    Carbohydrate oxidation as measured by breath samples

  • Exogenous carbohydrate oxidation rate (Part A) [ Time Frame: 120 min during trials 1-3 ] [ Designated as safety issue: No ]
    Carbohydrate oxidation as measured by breath samples

  • Exogenous carbohydrate oxidation rate (Part A) [ Time Frame: 150 min during trials 1-3 ] [ Designated as safety issue: No ]
    Carbohydrate oxidation as measured by breath samples

  • Exogenous carbohydrate oxidation rate (Part A) [ Time Frame: 180 min during trials 1-3 ] [ Designated as safety issue: No ]
    Carbohydrate oxidation as measured by breath samples

  • Endogenous carbohydrate oxidation (Part A) [ Time Frame: 30 min during trials 1-3 ] [ Designated as safety issue: No ]
    endogenous carbohydrate oxidation as measured through breath samples during trials 1-3

  • Endogenous carbohydrate oxidation (Part A) [ Time Frame: 60 min during trials 1-3 ] [ Designated as safety issue: No ]
    endogenous carbohydrate oxidation as measured through breath samples during trials 1-3

  • Endogenous carbohydrate oxidation (Part A) [ Time Frame: 90 min during trials 1-3 ] [ Designated as safety issue: No ]
    endogenous carbohydrate oxidation as measured through breath samples during trials 1-3

  • Endogenous carbohydrate oxidation (Part A) [ Time Frame: 120 min during trials 1-3 ] [ Designated as safety issue: No ]
    endogenous carbohydrate oxidation as measured through breath samples during trials 1-3

  • Endogenous carbohydrate oxidation (Part A) [ Time Frame: 150 min during trials 1-3 ] [ Designated as safety issue: No ]
    endogenous carbohydrate oxidation as measured through breath samples during trials 1-3

  • Endogenous carbohydrate oxidation (Part A) [ Time Frame: 180 min during trials 1-3 ] [ Designated as safety issue: No ]
    endogenous carbohydrate oxidation as measured through breath samples during trials 1-3

  • Glycogen utilization (Part B) [ Time Frame: 3 h post exercise during trials 4-6 ] [ Designated as safety issue: No ]

    Glycogen utilization measured through a muscle biopsy sample at post (~90 min), 3 and 6 h post exercise.

    Part B; trials 4-6.


  • Glycogen utilization (Part B) [ Time Frame: 6 h post exercise during trials 4-6 ] [ Designated as safety issue: No ]

    Glycogen utilization measured through a muscle biopsy sample at post (~90 min), 3 and 6 h post exercise.

    Part B; trials 4-6.



Secondary Outcome Measures:
  • Indirect calorimetry (Part A) [ Time Frame: every 30 min up to 180 min during trials 1-3 ] [ Designated as safety issue: No ]
    Measurements of VO2, VCO2 and RER through indirect calorimetry measured every 30 minutes during trials 1-3

  • Plasma glucose [ Time Frame: every 30 min up to 180 min during trials 1-6 ] [ Designated as safety issue: No ]
    Plasma glucose measurements

  • Plasma insulin [ Time Frame: every 30 minutes up to 180 min during trials 1-6 ] [ Designated as safety issue: No ]
    plasma insulin measurements


Estimated Enrollment: 17
Study Start Date: November 2012
Estimated Study Completion Date: January 2014
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Glucose-glucose
Glucose ingestion
Dietary Supplement: Carbohydrate ingestion
Various types of carbohydrate ingested during and following exercise
Active Comparator: Glucose-Fructose
glucose-fructose ingestion
Dietary Supplement: Carbohydrate ingestion
Various types of carbohydrate ingested during and following exercise
Active Comparator: disaccharide
Disaccharide ingestion
Dietary Supplement: Carbohydrate ingestion
Various types of carbohydrate ingested during and following exercise

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy
  • Male
  • 18 - 40 years of age
  • Endurance trained cyclist/triathlete
  • VO2 max ≥ 50 ml/kg/min
  • BMI < 25 kg/m2

Exclusion Criteria:

  • Use of medication
  • Smoking
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01709617

Contacts
Contact: Naomi Cermak, Ph.D. 31433881393 naomi.cermak@maastrichtuniversity.nl

Locations
Netherlands
Maastricht University Not yet recruiting
Maastricht, Limburg, Netherlands, 6200MD
Contact       ncermak@gmail.com   
Sponsors and Collaborators
Maastricht University Medical Center
Investigators
Principal Investigator: Luc van Loon, Ph.D. Maastricht University
  More Information

No publications provided

Responsible Party: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT01709617     History of Changes
Other Study ID Numbers: 12-3-048
Study First Received: October 11, 2012
Last Updated: October 16, 2012
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Maastricht University Medical Center:
carbohydrate, glycogen, glucose

ClinicalTrials.gov processed this record on September 29, 2014